Immunogenicity and Boosting After a Reduced Number of Doses of a Pneumococcal Conjugate Vaccine in Infants and Toddlers

Southern, Jo; Ashton, Lindsey; Richmond, Peter; Burbidge, Polly; Tasevska, Juliana; Crowley-Luke, Annette; Andrews, Nick; Morris, Rhonwen; Borrow, Ray; Cartwright, Keith; Miller, Elizabeth

doi:10.1097/01.inf.0000214921.52562.e5

Cited by 27 publications

(40 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…4,21 However, compared with previous term (PCV13) and preterm (PCV7) studies, antibody concentrations after primary and booster vaccination are lower overall, resulting in lower seroprotection after primary vaccination. 4,5,8,9,22 Similarly, compared with the recent PCV13 preterm study, 7 lower IgG GMCs and seroprotection rates were seen for all serotypes.…”

Section: Discussionmentioning

confidence: 82%

Schedules for Pneumococcal Vaccination of Preterm Infants: An RCT

Kent

Ladhani²,

Andrews

et al. 2016

Pediatrics

Self Cite

View full text Add to dashboard Cite

on behalf of the PUNS Study Group abstract BACKGROUND AND OBJECTIVE: Premature infants have a higher risk of invasive pneumococcal disease and are more likely to have lower vaccine responses compared with term infants. Increasingly, immunization schedules are including a reduced, 2-dose, pneumococcal conjugate vaccine priming schedule. Our goal was to assess the immunogenicity of 3 commonly used 13-valent pneumococcal conjugate vaccine (PCV13) priming schedules in premature infants and their response to a 12-month booster dose.

show abstract

Section: Discussionmentioning

confidence: 82%

Schedules for Pneumococcal Vaccination of Preterm Infants: An RCT

Kent

Ladhani²,

Andrews

et al. 2016

Pediatrics

Self Cite

View full text Add to dashboard Cite

show abstract

“…Antibody GMCs following PHiD-CV priming in our study were lower (non-overlapping 95% CIs) for 4 serotypes and in the same range or higher for the remaining 5 serotypes compared to a previous study with a 9-valent pneumococcal CRM 197 -conjugate post-booster antibody concentrations and OPA GMTs exceeded those measured following 2-dose catch-up immunization and further clinical data will be required to clarify the benefit of and/ or the need for a booster dose after 2-dose PHiD-CV catch-up immunization in the second year of life. As with other pneumococcal conjugate vaccines, [23][24][25] until the need for a booster dose is …”

Section: ©2 0 1 1 L a N D E S B I O S C I E N C E D O N O T D I S Tmentioning

confidence: 99%

Safety and immunogenicity of the 10-valent pneumococcal nontypeable Haemophilus influenzae protein D conjugate vaccine (PHiD-CV) in Chilean children

Lagos¹,

Muñoz²,

Levine³

et al. 2011

Human Vaccines

View full text Add to dashboard Cite

“…Avidity was measured by the thiocyanate elution assay (27), with minor modifications. Briefly, a serum dilution that yielded an optical density of 1.0 at 420 nm was calculated.…”

Section: Figmentioning

confidence: 99%

Concentration and High Avidity of Pneumococcal Antibodies Persist at Least 4 Years after Immunization with Pneumococcal Conjugate Vaccine in Infancy

Ekström¹,

Åhman²,

Palmu³

et al. 2013

Clin. Vaccine Immunol.

View full text Add to dashboard Cite

To provide more extensive evidence of long-term effects of vaccination on immunity against Streptococcus pneumoniae, a follow-up study of the Finnish Otitis Media (FinOM) Vaccine Trial was conducted. One of the objectives was to assess the persistence and avidity of pneumococcal antibodies 4 years after pneumococcal vaccination given in infancy. Children with complete follow-up in the FinOM trial up to 24 months of age were invited to a single visit in their fifth year of life. A blood sample was taken from all children for determination of anticapsular antibody concentrations to vaccine serotypes and avidity of antibodies to three serotypes. Children had been vaccinated at 2, 4, 6, and 12 months of age with 7-valent pneumococcal capsular polysaccharide, CRM197 conjugate vaccine (PCV7), or a control vaccine. Serum IgG antibody concentrations to vaccine serotypes remained significantly higher in children who had received PCV7 than in control children for 4 years after the fourth PCV7 dose. Concentrations of antibodies to frequently carried serotypes (6B and 19F) declined less than those of antibodies to a rarely carried serotype (4), suggesting that natural boosting contributed to antibody persistence. Furthermore, antibody avidity was significantly higher in PCV7 than control vaccine recipients. Four doses of PCV7 given in infancy elicit long-lasting antibody responses with high avidity. (This study has been registered at ClinicalTrials.gov under registration no. NCT00378417.)

show abstract

Immunogenicity and Boosting After a Reduced Number of Doses of a Pneumococcal Conjugate Vaccine in Infants and Toddlers

Cited by 27 publications

References 0 publications

Schedules for Pneumococcal Vaccination of Preterm Infants: An RCT

Schedules for Pneumococcal Vaccination of Preterm Infants: An RCT

Safety and immunogenicity of the 10-valent pneumococcal nontypeable Haemophilus influenzae protein D conjugate vaccine (PHiD-CV) in Chilean children

Concentration and High Avidity of Pneumococcal Antibodies Persist at Least 4 Years after Immunization with Pneumococcal Conjugate Vaccine in Infancy

Contact Info

Product

Resources

About